Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors

The dual protein kinase-transcription factor, ERK5, is an emerging drug target in cancer and inflammation, and small-molecule ERK5 kinase inhibitors have been developed. However, selective ERK5 kinase inhibitors fail to recapitulate ERK5 genetic ablation phenotypes, suggesting kinase-independent fun...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Nat Commun
Glavni autori: Lochhead, Pamela A., Tucker, Julie A., Tatum, Natalie J., Wang, Jinhua, Oxley, David, Kidger, Andrew M., Johnson, Victoria P., Cassidy, Megan A., Gray, Nathanael S., Noble, Martin E. M., Cook, Simon J.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7069993/
https://ncbi.nlm.nih.gov/pubmed/32170057
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-15031-3
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items